C4 Therapeutics (CCCC) Current Leases (2019 - 2026)

C4 Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• In Q1 2026, Current Leases rose 10.19% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (up 10.19% YoY), while the FY2025 annual figure was $6.4 million, up 10.27% from the prior year.
• Current Leases was $6.5 million for Q1 2026 at C4 Therapeutics, up from $6.4 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $6.5 million in Q1 2026 to a low of $1.7 million in Q1 2022.
• Historically, Current Leases has averaged $5.1 million across 5 years, with a median of $5.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Leases soared 288.87% in 2022, then increased 10.19% in 2026.
• A 5-year view of Current Leases shows it stood at $4.7 million in 2022, then advanced by 11.04% to $5.2 million in 2023, then advanced by 10.63% to $5.8 million in 2024, then gained by 10.27% to $6.4 million in 2025, then increased by 2.43% to $6.5 million in 2026.
• The last three Current Leases figures came in at $6.5 million (Q1 2026), $6.4 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.